Brainstorm Cell (Germany) Buy Hold or Sell Recommendation
| GHDN Stock | EUR 2.69 0.00 0.00% |
Assuming the 90 days trading horizon and your complete indifference towards market risk, our recommendation regarding Brainstorm Cell Therapeutics is 'Strong Hold'. Macroaxis provides Brainstorm Cell buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GHDN positions.
Check out Brainstorm Cell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Brainstorm and provide practical buy, sell, or hold advice based on investors' constraints. Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Brainstorm |
Execute Brainstorm Cell Buy or Sell Advice
The Brainstorm recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Brainstorm Cell Therapeutics. Macroaxis does not own or have any residual interests in Brainstorm Cell Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Brainstorm Cell's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Brainstorm Cell Trading Alerts and Improvement Suggestions
| Brainstorm Cell Ther generated a negative expected return over the last 90 days | |
| Brainstorm Cell Ther has high historical volatility and very poor performance | |
| Brainstorm Cell Ther has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Brainstorm Cell Therapeutics has accumulated 3.04 M in total debt with debt to equity ratio (D/E) of 934.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Brainstorm Cell Ther has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Brainstorm Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Brainstorm Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brainstorm Cell Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brainstorm to invest in growth at high rates of return. When we think about Brainstorm Cell's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (24.46 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Brainstorm Cell Therapeutics has accumulated about 6.22 M in cash with (26.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Roughly 23.0% of Brainstorm Cell shares are held by company insiders |
Brainstorm Cell Returns Distribution Density
The distribution of Brainstorm Cell's historical returns is an attempt to chart the uncertainty of Brainstorm Cell's future price movements. The chart of the probability distribution of Brainstorm Cell daily returns describes the distribution of returns around its average expected value. We use Brainstorm Cell Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Brainstorm Cell returns is essential to provide solid investment advice for Brainstorm Cell.
| Mean Return | -0.58 | Value At Risk | -6.03 | Potential Upside | 3.97 | Standard Deviation | 3.33 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Brainstorm Cell historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Brainstorm Cell Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Brainstorm Cell or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Brainstorm Cell's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Brainstorm stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.58 | |
β | Beta against Dow Jones | -0.11 | |
σ | Overall volatility | 3.35 | |
Ir | Information ratio | -0.22 |
Brainstorm Cell Volatility Alert
Brainstorm Cell Therapeutics exhibits very low volatility with skewness of -2.58 and kurtosis of 12.39. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Brainstorm Cell's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Brainstorm Cell's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Brainstorm Cell Fundamentals Vs Peers
Comparing Brainstorm Cell's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Brainstorm Cell's direct or indirect competition across all of the common fundamentals between Brainstorm Cell and the related equities. This way, we can detect undervalued stocks with similar characteristics as Brainstorm Cell or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Brainstorm Cell's fundamental indicators could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Brainstorm Cell to competition |
| Fundamentals | Brainstorm Cell | Peer Average |
| Return On Equity | -1.93 | -0.31 |
| Return On Asset | -0.68 | -0.14 |
| Current Valuation | 44.56 M | 16.62 B |
| Shares Outstanding | 36.54 M | 571.82 M |
| Shares Owned By Insiders | 22.70 % | 10.09 % |
| Shares Owned By Institutions | 10.41 % | 39.21 % |
| Price To Book | 36.30 X | 9.51 X |
| EBITDA | (24.28 M) | 3.9 B |
| Net Income | (24.46 M) | 570.98 M |
| Cash And Equivalents | 6.22 M | 2.7 B |
| Cash Per Share | 0.29 X | 5.01 X |
| Total Debt | 3.04 M | 5.32 B |
| Debt To Equity | 934.00 % | 48.70 % |
| Current Ratio | 0.97 X | 2.16 X |
| Book Value Per Share | 0.04 X | 1.93 K |
| Cash Flow From Operations | (26.27 M) | 971.22 M |
| Earnings Per Share | (0.68) X | 3.12 X |
| Target Price | 11.5 | |
| Number Of Employees | 43 | 18.84 K |
| Beta | -0.36 | -0.15 |
| Market Capitalization | 74.73 M | 19.03 B |
| Total Asset | 29.28 M | 29.47 B |
| Z Score | 14.4 | 8.72 |
| Net Asset | 29.28 M |
Brainstorm Cell Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Brainstorm . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Brainstorm Cell Buy or Sell Advice
When is the right time to buy or sell Brainstorm Cell Therapeutics? Buying financial instruments such as Brainstorm Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Brainstorm Cell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Brainstorm Cell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.